The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rini, B. I., Sosman, J. A., & Motzer, R. J. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05616.x · Cited by 51
RetractedSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citationNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Self-citationKabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., & Kolesnick, R. (2003) · Science · doi:10.1126/science.1082504 · Cited by 1,593
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Self-citationKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Self-citationTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationLymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., Choi, N. C., Mathisen, D., Wain, J., Mark, E. J., et al. (2002) · Science · doi:10.1126/science.1071420 · Cited by 967
Self-citationGorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 947
Repopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Self-citationHerbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
Bachelder, R. E., Crago, A. M., Chung, J., Wendt, M. A., Shaw, L. M., Robinson, G. S., & Mercurio, A. M. (2001) · PubMed · Cited by 487
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 486
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Self-citationCirculating endothelial cells: Biomarker of vascular disease
Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., Haubitz, M., Hebbel, R. P., Lip, G. Y. H., Mancuso, P., Sampol, J., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0578 · Cited by 390
Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 387
Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marm�, D., & Gastl, G. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1<178::aid-cncr25>3.0.co;2-7 · Cited by 372
Fan, F., Wey, J. S., McCarty, M. F., Belcheva, A., Liu, W., Bauer, T. W., Somcio, R. J., Wu, Y., Hooper, A., Hicklin, D. J., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208246 · Cited by 342
Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Self-citationEffect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 334
Imaging Angiogenesis: Applications and Potential for Drug Development
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., & Thrall, J. H. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji023 · Cited by 325
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz, T., Rawn, K., Voskas, D., Dumont, D. J., Ben-David, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.023 · Cited by 324
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
Increased incidence of matrix metalloproteinases in urine of cancer patients.
Moses, M. A., Wiederschain, D., Loughlin, K. R., et al. (1998) · PubMed · Cited by 261
Liu, G., Rugo, H. S., Wilding, G., McShane, T. M., Evelhoch, J. L., Ng, C., Jackson, E., Kelcz, F., Yeh, B. M., Lee, F. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.143 · Cited by 260
(2001) · PubMed · Cited by 257
(1992) · PubMed · Cited by 252
(1992) · PubMed · Cited by 247
ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage
Roy, R., Wewer, U. M., Zurakowski, D., Pories, S. E., & Moses, M. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409565200 · Cited by 244
Antiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Thomas, A. L., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228
The Role of Neuropilin in Vascular and Tumor Biology
Klagsbrun, M., Takashima, S., & Mamluk, R. (2002) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0119-0_3 · Cited by 220
(1991) · PubMed · Cited by 220
Hecht, J. R., Trarbach, T., Jaeger, E., Hainsworth, J., Wolff, R., Lloyd, K., Bodoky, G., Borner, M., Laurent, D., & Jacques, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba3 · Cited by 201
Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma
Nathanson, S. D., & Nelson, L. (1994) · Annals of Surgical Oncology · doi:10.1007/bf03187139 · Cited by 197
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Eskens, F. A. L. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601401 · Cited by 197
Wey, J. S., Fan, F., Gray, M. J., Bauer, T. W., McCarty, M. F., Somcio, R., Liu, W., Evans, D. B., Wu, Y., Hicklin, D. J., et al. (2005) · Cancer · doi:10.1002/cncr.21145 · Cited by 194
Interstitial fluid pressure in intracranial tumours in patients and in rodents
Boucher, Y., Salehi, H., Witwer, B., Harsh, G., & Jain, R. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.148 · Cited by 191
Self-citationHuber, P. E., Bischof, M., Jenne, J., Heiland, S., Peschke, P., Saffrich, R., Gröne, H.-J., Debus, J., Lipson, K. E., & Abdollahi, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1668 · Cited by 185
Saltz, L. B., Lenz, H.-J., Hochster, H., Wadler, S., Hoff, P., Kemeny, N., Hollywood, E., Gonen, M., Wetherbee, S., & Chen, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3508 · Cited by 183
Roh, H., Boucher, Y., Kalnicki, S., Buchsbaum, R., Bloomer, W. D., & Jain, R. K. (1991) · PubMed · Cited by 180
Self-citationMross, K., Drevs, J., Müller, M., Medinger, M., Marmé, D., Hennig, J., Morgan, B., Lebwohl, D., Masson, E., Ho, Y.-Y., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.005 · Cited by 165
Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment
Ansiaux, R., Baudelet, C., Jordan, B. F., Beghein, N., Sonveaux, P., De Wever, J., Martinive, P., Grégoire, V., Feron, O., & Gallez, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.743.11.2 · Cited by 163
Bocci, G., Man, S., Green, S. K., Francia, G., Ebos, J. M. L., du Manoir, J. M., Weinerman, A., Emmenegger, U., Ma, L., Thorpe, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0401 · Cited by 162
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Park, J. W., Kerbel, R. S., Kelloff, G. J., Barrett, J. C., Chabner, B. A., Parkinson, D. R., Peck, J., Ruddon, R. W., Sigman, C. C., & Slamon, D. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0785 · Cited by 159
Beaudry, P., Force, J., Naumov, G. N., Wang, A., Baker, C. H., Ryan, A., Soker, S., Johnson, B. E., Folkman, J., & Heymach, J. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2271 · Cited by 158
VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances
Rosen, L. S. (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-382 · Cited by 147
Vosseler, S., Mirancea, N., Böhlen, P., Mueller, M. M., & Fusenig, N. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3986 · Cited by 144
ATM regulates target switching to escalating doses of radiation in the intestines
Ch'ang, H.-J., Maj, J. G., Paris, F., Xing, H. R., Zhang, J. J., Truman, J., Cardon‐Cardo, C., Haimovitz‐Friedman, A., Kolesnick, R., & FUKS, Z. Y. (2005) · Nature Medicine · doi:10.1038/nm1237 · Cited by 143
Akagi, M., Kawaguchi, M., Liu, W., McCarty, M. F., Takeda, A., Fan, F., Stoeltzing, O., Parikh, A. A., Jung, Y. D., Bucana, C. D., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600811 · Cited by 133
Teicher, B. A. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437479 · Cited by 125
Taguchi, T. (1995) · PubMed · Cited by 117
Bevacizumab—current status and future directions
Midgley, R. S., & Kerr, R. S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi208 · Cited by 96
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
Mundhenke, C., Thomas, J. P., Wilding, G., Lee, F. T., Kelzc, F., Chappell, R. J., Neider, R. S., Sebree, L., & Friedl, A. (2001) · PubMed · Cited by 87
Segers, J., Fazio, V. D., Ansiaux, R., Martinive, P., Féron, O., Wallemacq, P. E., & Gallez, B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.017 · Cited by 80
Identification of Clinically Useful Cancer Prognostic Factors: What Are We Missing?
McShane, L. M., Altman, D. G., & Sauerbrei, W. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji193 · Cited by 79
Clinical implications of antiangiogenic therapies.
Sehn, L. H., & Connors, J. M. (2005) · PubMed · Cited by 67
Salnikov, A. V., Roswall, P., Sundberg, C., Gardner, H., Heldin, N., & Rubin, K. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700252 · Cited by 58
Encouraging Results for Second-Generation Antiangiogenesis Drugs
Marx, J. L. (2005) · Science · doi:10.1126/science.308.5726.1248 · Cited by 52
Tumor Growth: A Putative Role for Platelets?
Verheul, H. M. W., & Pinedo, H. M. (1998) · The Oncologist · doi:10.1634/theoncologist.3-2-0 · Cited by 45
Multi-kinase inhibitors create buzz at ASCO
Branca, M. A. (2005) · Nature Biotechnology · doi:10.1038/nbt0605-639 · Cited by 38
Expanding the Clinical Development of Bevacizumab
Chen, H. X. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-27 · Cited by 37
Jennens, R. R., Rosenthal, M. A., Lindeman, G. J., et al. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.01.011 · Cited by 33
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationAngiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Metadata
- Authors
- Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S.
- Venue
- Nature Clinical Practice Oncology
- Published
- 2006-01
- Volume
- 3
- Issue
- 1
- Pages
- 24-40
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- OpenAlex
- W1996810856
- Cited by
- 1,039
- References
- 87
- FWCI
- 43.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.